Search Orphan Drug Designations and Approvals
-
| Generic Name: | BMPRII: ALK1 bispecific clustering agonist antibody |
|---|---|
| Date Designated: | 06/09/2025 |
| Orphan Designation: | treatment of hereditary hemorrhagic telangiectasia |
| Orphan Designation Status: | Designated |
| FDA Orphan Approval Status: | Not FDA Approved for Orphan Indication |
| Sponsor: |
Diagonal Therapeutics 200 Arsenal Yard Blvd Suite 220 Watertown, Massachusetts 02472 United States The sponsor address listed is the last reported by the sponsor to OOPD. |
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-







